Evidence map›Paper›PMID 33447690›Full record

ArticleJournal of the Endocrine Society2021

11-Oxygenated Androgens Useful in the Setting of Discrepant Conventional Biomarkers in 21-Hydroxylase Deficiency.

Smita Jha, Adina F Turcu, Ninet Sinaii, Brittany Brookner, Richard J Auchus, Deborah P Merke

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. 24-Hour Profiles of 11-Oxygenated CFrontiers in endocrinology · 2021
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Disorders of Sex Development of Adrenal Origin.Frontiers in endocrinology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Smita JhaSection on Congenital Disorders, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0001-9201-3340
Adina F TurcuDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.
Ninet SinaiiBiostatistics and Clinical Epidemiology Service, National Institutes of Health, Bethesda, MD, USA.
Brittany BrooknerSection on Congenital Disorders, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0002-7372-9340
Richard J AuchusDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-6815-6181
Deborah P MerkeSection on Congenital Disorders, National Institutes of Health Clinical Center, Bethesda, MD, USA.ORCID 0000-0002-3746-0460
University of Michigan · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USNational Institutes of Health Clinical Center · US

Funding

The contemporary endocrinology of congenital adrenal hyperplasiaK08DK109116 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TURCU, ADINA F · 2016 to 2020
$832k
Natural History Study of Patients with Excess AndrogenZIAHD008934 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI MERKE, DEBORAH · 2013 to 2021
$238k
NIDDK NIH HHS K08 DK109116
6 · The paper itself

Abstract

contextSerum 17-hydroxyprogesterone (17OHP) and androstenedione (A4) are the conventional biomarkers used to assess disease control in patients with 21-hydroxylase deficiency (21OHD). However, discrepancy between the two is not uncommon, limiting interpretation.

objectiveTo evaluate 11-oxyandrogens in discriminating good versus poor disease control in 21OHD in the setting of discrepant 17OHP and A4.

methodsRetrospective analysis of 2738 laboratory assessments obtained as part of Natural History Study of congenital adrenal hyperplasia (CAH) at the National Institutes Health Clinical Center. Patients with discrepant 17OHP and A4 and available sera were selected. A 15-steroid mass-spectrometry panel was performed in sera from patients with 21OHD and age- and sex-matched controls. Patients were categorized in "good" or "poor" control based on clinical assessment (bone age advancement, signs and symptoms of precocious puberty, menstrual irregularity, hirsutism, or hypogonadotrophic hypogonadism).

resultsDiscrepant 17OHP and A4 was found in 469 (17%) laboratory assessments. Of these, 403 (86%) had elevated 17OHP with A4 in reference range. Of 46 patients with available sera, 30 (65%) were in good control. Median fold elevation relative to controls was higher in patients with poor versus good control for 11-hydroxytestosterone (median [interquartile range], 2.82 [1.25-5.43] vs 0.91 [0.49- 2.07],

conclusion11-Oxyandrogens, especially 11-hydroxytestosterone, may be useful in the management of CAH when conventional biomarkers are inconclusive.

Indexed as

alternate androgensandrogen excessbiomarkerscongenital adrenal hyperplasiamonitoring therapysteroidogenesis

Identifiers

PMID33447690
PMCPMC7796775
OpenAlexW3123696312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.